Results 81 to 90 of about 2,521 (195)

Contraception with estradiol valerate and dienogest: adherence to the method

open access: yes, 2019
Franca Fruzzetti,1 Anna Maria Paoletti,2 Tiziana Fidecicchi,1 Giulia Posar,1 Riccardo Giannini,3 Marco Gambacciani11Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy; 2Department of Obstetrics and Gynecology, Cagliari ...
Posar G   +5 more
core  

Dienogest in the Treatment of Endometriosis [PDF]

open access: yesGlobal Journal of Reproductive Medicine, 2017
Endometriosis is a prevalent chronic disease in up to 10% of women of reproductive age and often causes pain symptoms. In some patients, these symptoms negatively affect quality of life for a long time. Dienogest is an oral progestin that was recently approved for the treatment of endometriosis.
openaire   +1 more source

Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill

open access: yes, 2010
The aim of this review is to define the role of the combined dienogest (DNG)/estradiol valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and pharmacological effects and clinical application as well.
Scala Maria   +11 more
core   +1 more source

The Effect of Rubus idaeus Polyphenols Extract in Induced Endometriosis in Rats

open access: yesMolecules
Endometriosis is a common gynecological condition with a complex physio-pathological background. This study aimed to assess the role of Rubus idaeus leaf extract (RiDE) as a potential therapeutic agent in reducing the size of the endometriotic lesions ...
Elena-Mihaela Jianu   +13 more
doaj   +1 more source

Effect of Elagolix in comparison to Dienogest in the treatment of symptomatic adenomyosis

open access: yes
Background: Adenomyosis, a benign gynecological disorder, is diagnosed with increasing frequency in infertile patients since women delay their first pregnancy.
Anwary, Shaheen Ara   +7 more
core   +1 more source

Hormonale Kontrazeption mit einem Dienogest-haltigen Präparat: Ergebnisse einer 7-Jahres-Studie [PDF]

open access: yes, 2005
Das orale Kontrazeptivum Valette© der Firma Jenapharm enthält die Wirkstoffe Ethinylestradiol (0,03 mg) und Dienogest (2,0 mg). In der ersten und bisher einzigen Langzeituntersuchung über das neue Gestagen Dienogest wurden die Einflüsse auf den ...
Noack, Julia
core  

Effect of dienogest on endometrial morphology and function with external genital endometriosis [PDF]

open access: yesГинекология, 2014
In this paper we investigate the effect of dienogest on endometrial morphology and function in patients with external genital endometriosis. It is shown that dienogest is effective in reducing pain in patients with external genital endometriosis and ...
A M Gerasimov   +3 more
doaj  

Norethindrone acetate versus dienogest for pain relief in endometriosis related pain: A randomized controlled trial

open access: yes
Objective: To determine which progestin, norethindrone acetate (NETA) or dienogest, is more effective in alleviating pain associated with endometriosis? Study design: This single-center, prospective, randomized trial included 70 patients aged 18-40 years
Aslan, Kiper   +4 more
core   +1 more source

Modern progestogens in the treatment of genital endometriosis

open access: yesРепродуктивная эндокринология
Objective of the review: to evaluate modern approaches to the use of progestogens for the treatment of endometriosis, using literature sources, to provide examples of their effectiveness in global and own practices. Analysis of literary data.
L.B. Markin, O.O. Matvienko
doaj   +1 more source

The effects of vaginal bromocriptine and dienogest on women with adenomyosis: a clinical study

open access: yesMiddle East Fertility Society Journal
Objective Adenomyosis occurs when endometrial glands and stroma develop in the myometrium, leading to symptoms such as pelvic pain and heavy menstrual bleeding. Method This randomized, double-blinded, controlled trial study was conducted on patients with
Parvane Bahoorzahi   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy